VIR VIR BIOTECHNOLOGY INC
FollowCOM (common), issuer CIK 1706431
Filings received so far for Q3 2026: 6 13F filers report a position in VIR shares at 2026-09-30. The quarter is not complete: its 13F deadline is 2026-11-14, and the counts grow as filings arrive.
13D and 13G filers
No 13D or 13G on this security in the data. Structured 13D/G data starts 2024-12-18.
Insider trades
No Form 4 transaction on this security in the data.
13F holders, Q3 2026
Filers in the available 13F reports with a share position at 2026-09-30, filer groups collapsed to one row (method), largest first. Options and principal amounts are left out. A group row states no % of portfolio, since each member reports its own portfolio: the members' percents are listed under it. A value about 1,000 times or 1/1,000 of the price other filers imply is shown as filed but neither ranks the row nor enters a sum.
| Holder | Shares | Value | % of portfolio | Change | Source |
|---|---|---|---|---|---|
| GAMMA Investing LLC | 5,815 | $65K | <0.01% | +695 | 13F-HRTimeline |
| Versant Capital Management, Inc | 2,690 | $30.1K | <0.01% | 0 | 13F-HRTimeline |
| Farther Finance Advisors, LLC | 397 | $4.44K | <0.01% | -241 | 13F-HRTimeline |
| MassMutual Private Wealth & Trust, FSB | 323 | $3.61K | <0.01% | 0 | 13F-HRTimeline |
| GILPIN WEALTH MANAGEMENT, LLC | 12 | $135 | <0.01% | -5 | 13F-HRTimeline |
| Davis Capital Management | 6 | $67 | <0.01% | 0 | 13F-HRTimeline |
Events
Sawaf Aziz reported holdings of VIR shares in a Form 3 filed 2026-10-06. 0001628280-26-065222
Accepted , ingested